US EditionPoolbeg Pharma (AIM: POLB) POLB 001 LPS Challenge Trial Paper Published
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
Poolbeg Pharma plc - Peer-Reviewed POLB 001 LPS Challenge Trial Paper Published in Frontiers in Immunology
28 January 2026 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces the publication of a peer-reviewed paper from the POLB 001 LPS human challenge trial in Frontiers in Immunology. Read more… The post Poolbeg Pharma plc – Peer-Reviewed POLB 001 LPS Challenge Trial Paper Published in Frontiers in Immunology appeared first …
Poolbeg Pharma (AIM: POLB) POLB 001 LPS Challenge Trial Paper Published
Peer-Reviewed POLB 001 LPS Challenge Trial Paper Published in Frontiers in Immunology 28 January 2026- Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company with a core focus on transforming theRead More...
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium